DMT for Anxiety Disorders

23 papers and 1 clinical trial exploring dmt as a treatment for anxiety disorders.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

23 papers
Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
Journal
Neuropsychopharmacology
Authors
Almeida, R., Araújo, D. B., Arcoverde, E., Arichelle, F., Barbosa, D. C., Barros, H., Bolcont, R., Costa-Macedo, J. V., da Costa Bezerra, R. B., da Cruz Nunes, J. A., Dantas Correa, L., de Araujo Costa Neto, L. A., Falchi-Carvalho, M., Florence-Vilela, R., Galvão-Coelho, N. L., Laborde, S., Macedo, R. K. A., Montanini, D., Nunes Ferreira, L. F., Palhano-Fontes, F., Pantrigo, E. J., Silva, S. R. B., Teixeira, E., Wießner, I.
Open Accessindividual

Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants

In a double‑blind, placebo‑controlled crossover study in 22 healthy adults, continuous DMT infusions showed dose‑proportional pharmacokinetics and rapidly produced dose‑dependent subjective effects that plateaued after 30 minutes with a ceiling for positive effects at 1.8 mg/min, whereas 2.4 mg/min increased anxious ego dissolution and anxiety and produced moderate acute tolerance. A self‑guided titration enabled participants to achieve effects comparable to the 1.8 mg/min dose, supporting dose‑finding and adjustable dosing strategies for future DMT research.

Published
Journal
Neuropsychopharmacology
Authors
Becker, A. M., Eckert, A., Erne, L., Klaiber, A., Liechti, M. E., Luethi, D., Müller, L., Nuraj, A., Rudin, D., Varghese, N., Vogt, S. B., Zuparic, M.
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
Journal
JAMA Psychiatry
Authors
Graziosi, M., Hinkle, J. T., Nayak, S., Yaden, D. B.
Paywallindividual

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial

In a single-blind proof-of-concept trial in 11 college students with harmful alcohol use, one dose of ayahuasca with psychological support was well tolerated and produced a short-term reduction in days drinking at 2–3 weeks that did not survive correction for multiple comparisons. The study demonstrates feasibility of the protocol and supports larger, controlled trials to assess efficacy.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Bouso, J. C., de Lima Osório, F., Dos Santos, R. G., Guerra, L. T. L., Hallak, J. E., Maekawa, R. M., Paranhos, B. A. P. B., Rodrigues, L. S., Rossi, G. N., Santos, F. P., Yonamine, M.

Clinical Trials

1 trial

Explore further

Search all DMT papers Search all Anxiety Disorders trials Full DMT profile Full Anxiety Disorders profile